UOC
OVID icon

UBS O'Connor’s Ovid Therapeutics OVID Stock Holding History

UBS O'Connor’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-943,416
Closed -$881K – 425
2024
Q4 		$881K Buy
943,416
+315,126
+50% +$353K 0.02% 242
2024
Q3 		$741K Buy
628,290
+340,000
+118% +$355K 0.02% 308
2024
Q2 		$222K Buy
288,290
+28,790
+11% +$80.1K 0.01% 415
2024
Q1 		$791K Buy
259,500
+115,000
+80% +$385K 0.02% 299
2023
Q4 		$465K Sell
144,500
-5,500
-4% -$18.8K 0.01% 358
2023
Q3 		$576K Buy
150,000
+20,000
+15% +$71.9K 0.01% 391
2023
Q2 		$426K Buy
+130,000
New +$441K 0.01% 455

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

UBS O'Connor's OVID Position: Q1 2025 in Review

UBS O'Connor sold out of Ovid Therapeutics (OVID) in Q1 2025, closing a stake of 943,416 shares — an estimated $881K sold.

UBS O'Connor first reported a position in OVID in Q2 2023 and held it in 7 quarters. The position peaked at $881K in Q4 2024. 82 funds tracked by Wall St. Rank hold OVID as of Q1 2025.

  • UBS O'Connor reported no remaining Ovid Therapeutics position as of Q1 2025 after selling out during the quarter.
  • UBS O'Connor sold 943,416 Ovid Therapeutics shares in Q1 2025, an estimated $881K.
  • UBS O'Connor first reported a position in Ovid Therapeutics in Q2 2023 and held it in 7 quarters.
  • UBS O'Connor's Ovid Therapeutics position peaked at $881K in Q4 2024.
  • 82 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2025.

Based on UBS O'Connor's 13F filing for Q1 2025, filed 15 May 2025.